Overview
- - The NHS has begun offering tirzepatide (Mounjaro) to a narrowly defined group, with Norfolk and Waveney’s Integrated Care Board projecting more than 11,000 eligible under strict criteria.
- - Eligibility locally is reported to require a BMI over 40 plus at least four qualifying weight‑related conditions, reflecting a tightly controlled rollout.
- - Tirzepatide is a once‑weekly injection that suppresses appetite, widely obtained privately since early 2024 and now entering supervised NHS use for those who meet clinical need.
- - Local accounts describe substantial weight loss when paired with lifestyle changes, while other testimonies cite severe nutrient deficiencies, tachycardia and emergency care after dose escalation.
- - Eli Lilly says the drug should be used only under prescription and notes increased heart rate as a listed side effect, as clinicians caution against cosmetic use and warn weight can return if treatment stops.